HC Wainwright Reiterates “Buy” Rating for Cardiff Oncology (NASDAQ:CRDF)

HC Wainwright reissued their buy rating on shares of Cardiff Oncology (NASDAQ:CRDF) in a research report report published on Monday, Benzinga reports. They currently have a $14.00 price target on the stock. HC Wainwright also issued estimates for Cardiff Oncology’s FY2024 earnings at ($0.98) EPS.

Separately, Piper Sandler increased their target price on shares of Cardiff Oncology from $5.00 to $7.00 and gave the stock an overweight rating in a research note on Friday, March 1st.

Cardiff Oncology Stock Performance

Shares of CRDF opened at $3.38 on Monday. The business’s 50-day moving average is $4.66 and its two-hundred day moving average is $2.55. The company has a market capitalization of $151.15 million, a P/E ratio of -3.76 and a beta of 2.02. Cardiff Oncology has a fifty-two week low of $0.94 and a fifty-two week high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. Cardiff Oncology had a negative return on equity of 54.54% and a negative net margin of 6,594.92%. The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.08 million. Analysts forecast that Cardiff Oncology will post -0.97 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Callan Capital LLC lifted its position in Cardiff Oncology by 129.2% during the third quarter. Callan Capital LLC now owns 31,147 shares of the company’s stock worth $43,000 after buying an additional 17,560 shares in the last quarter. Blair William & Co. IL grew its holdings in Cardiff Oncology by 32.4% in the 1st quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock valued at $919,000 after buying an additional 42,180 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Cardiff Oncology during the 1st quarter worth $1,351,000. Finally, PFG Investments LLC acquired a new position in shares of Cardiff Oncology during the 1st quarter valued at about $53,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.